In a multicenter study, the CRP levels were used to monitor the clinical response between the anti-TNF drug Adalimumab and biosimilars in IBD patients, both CD and UC; no significant difference was found in CRP levels between patients switching from the originator to biosimilar or between biosimilars [36]. The gene discussed is CRP; the disease is inflammatory bowel disease.